OMRON (6645) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Jun, 2025Executive summary
FY2024 net sales decreased 2.1% year-over-year to ¥801.8bn, mainly due to weak demand in Industrial Automation and Devices & Module Solutions, and lower demand in China for Healthcare.
Operating income rose 57.4% year-over-year to ¥54.0bn, driven by improved margins and cost reductions from structural reforms.
Net income attributable to shareholders doubled to ¥16.3bn, despite one-time restructuring costs.
Structural reform expenses totaled ¥27.8bn, including ¥22.0bn for headcount and capacity optimization.
IAB and SSB segments achieved profit growth, while HCB and DMB faced declines from weak demand and competition.
Financial highlights
Gross profit margin improved by 2.2 percentage points to 44.5%; operating income margin increased to 6.7% from 4.2%.
Free cash flow turned positive at ¥7.9bn, up ¥70.1bn year-over-year; cash and equivalents rose to ¥149.0bn.
Net income per share increased to ¥82.63.
Dividend payout ratio reached 253.3%.
ROE improved to 2.1% from 1.1%; ROIC rose to 1.8% from 1.0%.
Outlook and guidance
FY2025/FY2026 forecasts presented as a range due to U.S. tariff policy uncertainty; net sales expected between ¥820.0bn and ¥835.0bn, operating income between ¥56.0bn and ¥65.0bn.
Net income forecasted at ¥29.0bn–¥35.5bn; ROE and ROIC expected to rise to approximately 3–4%.
Full-year dividend guidance maintained at ¥104 per share.
Guidance reflects up to ¥16bn profit and ¥15bn sales risk from U.S. tariffs.
Increased R&D investment in IAB by ¥5bn year-over-year to strengthen competitiveness.
Latest events from OMRON
- Revenue and net sales up YoY, net income nearly doubled, and full-year guidance raised.6645
Q3 20265 Feb 2026 - Sales up 5%, profit guidance raised as automation and data outperform, healthcare lags.6645
Q2 202619 Nov 2025 - Net income rebounded to ¥6.8bn as automation and device growth offset healthcare weakness.6645
Q1 20266 Aug 2025 - Sales and profit fell sharply on restructuring costs, but full-year outlook is maintained.6645
Q1 202513 Jun 2025 - Full-year profit guidance raised and dividends maintained despite lower sales and restructuring costs.6645
Q2 202513 Jun 2025 - Profit outlook raised as margin gains offset sales drop and restructuring costs.6645
Q3 20259 Jun 2025